Background: Relative to traditional fee-for-service Medicare, managed care plans caring for Medicare beneficiaries may be better positioned to promote recommended services and discourage burdensome procedures with little clinical value at the end of life.
E xcessive health care utilization at the end of life can be burdensome for patients and of little clinical value. Previous studies of the Medicare population have shown high rates of hospitalization and use of intensive procedures at the end of life, with approximately one quarter of total annual Medicare outlays spent on people in their last year of life. [1] [2] [3] Similar to the US health care system more broadly, considerable geographic variation exists in end-of-life care, and studies have found little correlation between greater treatment intensity and better quality care. 4, 5 In addition to the cultural and professional norms that shape physician behavior, a key determinant of older patients' end-of-life care may relate to the fragmented fee-for-service delivery system that defines the traditional Medicare (TM) program. 6 Relative to TM, managed care plans may be better positioned to promote the use of recommended services such as hospice care at the end of life while discouraging the use of unnecessary, invasive procedures. 7 Medicare Advantage (MA) plans generally are paid on a per-person-rather than per-service-basis, thereby rewarding plan efforts to manage chronic disease and to minimize treatment intensity overall. 8 Little prior research, however, has characterized the intensity or quality of end-of-life care within Medicare's managed care program. Such information has become increasingly important, as the proportion of Medicare beneficiaries in managed care has grown to almost 30%. 9, 10 Hospice is one of the few benefits "carved out" of Medicare's managed care program. 11 When managed care enrollees enroll in hospice, fee-for-service Medicare becomes the payer for both hospice care and care unrelated to the terminal condition; health plans remain liable only for any supplemental benefits they provide beyond those in TM, such as vision or dental care. This policy, which dates back to the origins of the Medicare hospice benefit and risk-based contracting in 1982, creates a strong financial incentive for plans to promote hospice enrollment among their more expensive terminally ill enrollees. Previous studies using data from the 1990s confirmed higher rates of hospice enrollment in Medicare managed care versus TM while concluding that this elevated use did not appear inappropriate. [12] [13] [14] Yet, these data are now almost 2 decades old and preceded passage of the Medicare Modernization Act of 2003, which has led to markedly increased enrollment of Medicare beneficiaries in managed care plans. 15 We compared service use and hospice enrollment at the end of life for individuals enrolled in MA plans relative to similar individuals enrolled in TM for the time period 2003-2009. To our knowledge, this study is the first to compare intensity of inpatient and ambulatory services used at the end of life across these 2 main components of the Medicare program.
METHODS

Overview
We used individual-level Healthcare Effectiveness Data and Information Set (HEDIS) data on service utilization that MA plans are required to submit annually to the Centers for Medicare and Medicaid Services (CMS). Following previous work, 16 we then constructed comparable measures based on exact specifications provided by the National Committee for Quality Assurance (NCQA) using data from a 20% random sample of TM beneficiaries. We used the Medicare beneficiary summary file to capture date of death and the hospice file to capture hospice use by MA and TM decedents. We then analyzed service use in the calendar year of death for all continuously enrolled MA and TM decedents aged 65 and above, reweighting TM samples to match MA distributions by age, sex, race, and geography to account for observable differences between MA and TM enrollees. 17 
MA Data
For 2003-2009, we used individual-level HEDIS utilization data to create our measures of interest, linking these data to the Beneficiary Summary File using a confidential identifier from CMS. 18 Although HEDIS utilization data are not fully audited, CMS has audited the subset of measures used to assess Medicare HMOs' clinical quality and found them to be highly accurate and consistent with technical specifications provided by the NCQA. 19 We focused on overall rates of medical and surgical hospitalizations and days, ambulatory visits, ambulatory surgical procedures, and emergency department visits. Each MA plan reports utilization at the beneficiary-year level according to NCQA specifications. Thus, for enrollees who died in a particular month, data included all utilization from January 1 of the death year until the date of death.
We excluded observations from the small number of preferred provider organizations in our dataset, legacy health plans that were reimbursed on a cost basis rather than by capitation, and special needs plans that serve nonrepresentative beneficiaries. We also excluded private feefor-service plans because they were not required to report HEDIS utilization data. Finally, we excluded health plans with < 500 enrollees, which account for < 0.2% of enrollees across the years. The Medicare Advantage health maintenance organization (MA-HMO) plans that are the focus of the study accounted for approximately 65% of all MA enrollees in 2009.
TM Data
We used claims data from a 20% random sample of beneficiaries aged 65 and above who were continuously enrolled in Medicare Parts A and B in their calendar year of death. We excluded from our sample long-stay nursing home residents whom we identified using a validated claims-based algorithm 20 and individuals with end-stage renal disease. For all HEDIS utilization categories, we applied NCQA specifications to count the number of times each person underwent each procedure.
Using the Medicare hospice file, we captured all hospice use during each of the study years. For MA and TM hospice enrollees alike, fee-for-service Medicare pays hospice agencies for care related to the terminal condition and pays other providers for care not-related to the terminal condition (as noted above, MA plans remain liable only for supplemental benefits for members enrolled in hospice).
Statistical Analyses
For MA and TM decedents, we obtained information on the race/ethnicity, age, sex, and zip code of residence from the Medicare Beneficiary Summary File, linked separately to each dataset. In each service category, we compared utilization for MA decedents in a given year with a sample of TM decedents who died in the same calendar year, weighting the TM sample to match the MA sample distribution by demographic traits (individual-level age, sex, and race) and geographic area. Almost all reweighting occurred at the zip code (60%) or county (36%) levels. Weighting to match on geography helped control for variations in practice patterns and health care system characteristics within Medicare across regions. 21 In addition, by matching at the zip code or county level, we partially controlled for unmeasured socioeconomic characteristics associated with area of residence. We aggregated these results to create national estimates. Because the HEDIS use data are reported by calendar year rather than by service date, we compared service use in the calendar year of death rather than over a fixed interval (eg, last 6 mo of life) preceding death. The Technical Appendix contains further information on the weighting process (see Technical Appendix, Supplemental Digital Content 1, http:// links.lww.com/MLR/A543).
We first present demographic traits of MA and TM decedents (overall and weighted to match MA distributions) for the first and last years of our study period. These estimates include information from the US Census that was merged with our data based on zip code. In addition, although our analyses focus on continuously enrolled individuals, we estimate disenrollment among all MA decedents across study years to characterize the extent to which disenrollment in the face of serious illness might bias our results. We present information on hospice use and length-of-use by all MA and TM decedents (not limited to our matched sample) across study years. Finally, we present mean service use by matched MA and TM decedents and relative differences between the two. Although we could distinguish MA and TM enrollees in the hospice claims, we only were able to link hospice enrollment and our other utilization measures at the individual level for TM decedents (the terms of our Data Use Agreement did not allow this for MA enrollees). Consequently, all service use comparisons account for year-to-year differences in the level and duration of hospice use among MA and TM decedents at an aggregate level, both for services related to the terminal condition (captured in the hospice per-diem) and for services unrelated to the terminal condition (captured in the fee-forservice data for both MA and TM decedents), described further in the Technical Appendix.
RESULTS
Reflecting the increased proportion of Medicare beneficiaries enrolled in MA, the number of MA decedents in our study population increased from 150,679 in 2003 to 248,676 in 2009, and the number of TM decedents in our 20% sample decreased from 206,000 to 190,000 over the same time period (Table 1) . Compared with TM decedents, MA decedents were somewhat younger; less likely to live in poor communities (9.5% vs. 10.9% among MA and TM decedents, respectively, in 2009); more likely to be black (10.7% vs. 7.8%) or Hispanic (3.1% vs. 1.5%); and more likely to live in urban areas (87.7% vs. 72.3%). Similar differences before matching existed across study years. After reweighting the TM sample distribution, no observable differences remained in characteristics between the MA and TM cohorts.
Disenrollment rates among MA decedents during the calendar year of death generally were < 5% between 2003 and 2009 (a rate similar to MA nondecedents), suggesting that individuals did not disenroll in disproportionately large numbers as they approached death (see Appendix Table 1 , Supplemental Digital Content 2, http://links.lww.com/MLR/ A544). Hence, limiting our sample to continuously enrolled individuals had little effect on the sample size.
Hospice Use
Hospice use among both MA and TM decedents increased over the study period ( Fig. 1) . Hospice use in the year before death was 9 percentage points higher among MA decedents than for TM decedents in 2003 (38% vs. 29%), but the difference narrowed over the 6-year study period (46% vs. 40% in 2009). Although average length-of-use for MA and TM hospice enrollees was comparable over the study period, it diverged somewhat in recent years as length-of-use continued to increase in MA while leveling off in TM (Fig. 2) . Comparing MA and TM hospice length-of-use distributions, this recent difference reflects a relatively smaller share of MA hospice users with hospice stays of 0-3 days (16.6% and 18.4% of MA and TM hospice users in 2009, respectively) and a relatively larger share of MA hospice users with hospice stays between 61 and 180 days [14. 6% and 13.5% of MA and TM hospice users in 2009, respectively (not shown)]. 
Service Use
DISCUSSION
MA enrollees used hospice more frequently at the end of life than those being cared for in TM, but this difference narrowed over the study period. Perhaps more important, we found that MA-HMO enrollees used fewer inpatient services overall and had markedly lower emergency department use at the end of life compared with matched TM enrollees. These differences remained after accounting for greater 28 hospice enrollment among MA versus TM decedents and were consistent in direction and magnitude across the 7-year study period. Not all service categories had consistently lower use by MA decedents. Inpatient surgical admissions and outpatient physician visits were modestly higher for MA decedents in more recent years, and initially large, negative differences in inpatient surgical days and ambulatory surgery and procedures have diminished. Our analyses build on previous research finding greater hospice use in MA versus TM by revealing a narrowing difference in hospice enrollment and generally comparable length-of-use trends. [12] [13] [14] MA plans have strong financial incentives to enroll patients in hospice, because they are not financially responsible for care of these relatively costly individuals once they enroll in hospice. 22 Although these financial incentives were unchanged, TM hospice enrollment grew almost twice as fast as MA hospice enrollment over the study period, perhaps suggesting a broader recognition of hospice's potential benefits and a more active effort by hospice agencies to increase enrollment. 23 Our findings have important implications for policy, especially as greater attention is devoted to the MA program and to integrated care and cost containment initiatives more broadly. [24] [25] [26] As expected, we found lower use of hospital services for decedents enrolled in capitated MA plans relative to TM. Although we could not assess the appropriateness of services, some of our findings suggest that MA plans may do a better job of managing care at the end of life. The substantially lower rates of emergency department visits and inpatient medical hospitalizations among MA decedents suggest that plans treat patients at the end of life in less costly settings and may reduce avoidable hospitalizations more effectively, in part through greater use of hospice. The consistent and substantially lower rates of emergency department use among MA decedents are especially striking given recent findings documenting the common pathway between emergency department use, hospitalizations, and death in the hospital for individuals at the end of life. 27 Our data did not permit us to determine the mechanisms by which MA plans achieve lower utilization at the end of life relative to TM. In particular, we were unable to determine the extent to which utilization differences were driven by better coordination of care, potentially leading to reductions of inappropriate services, or by reductions in appropriate services. Similarly, because HEDIS utilization data are reported at the beneficiary-calendar year level, we are unable to pinpoint the specific timing of the service use differences we observe. In addition, utilization differences between MA and TM decedents may reflect unobserved differences in patient preferences (eg, if MA enrollees were less inclined to pursue intensive services at the end of life).
Looking ahead, Medicare beneficiaries' end-of-life care likely will be shaped increasingly by more integrated financing and delivery systems, including MA plans and newer innovations such as Accountable Care Organizations and Patient Centered Medical Homes. 28 Accountable Care Organizations may have a stronger incentive than MA plans to adopt management practices aimed at optimizing palliative care, rather than simply attempting to enroll patients in hospice care at the earliest possible time. As these changes occur, policymakers must be mindful of the potential strengths and limitations these approaches hold for individuals at the end of life. More specifically, relevant policies should seek to ensure adequate provider networks for patients (eg, including access to palliative care specialists), suitable quality measurement for oversight, and sufficiently flexible financial incentives to foster coordination of care and mitigate incentives for selection or stinting on needed care.
Our study has several limitations. As with other observational studies, unobserved differences between MA and TM enrollees (ie, selection) rather than MA plan practices may account for the differences observed in service use at the end of life. Our weighted analyses matched distributions by age, sex, race, and geographic area, but we were unable to match on diagnoses or prior health status. Thus, it is possible that unobserved patient differences could account for our findings, in part. Nonetheless, the magnitude and direction of the differences we detected are generally consistent across study years, despite a considerable transformation in the plans and enrollees participating in the MA program. More specifically, although recent analyses show that selection into MA relative to TM diminished greatly in the 2006-2008 time period (along dimensions of health status, health care use, and total health care spending), 29, 30 many of the trends we detected were consistent across the 7-year study period.
Our analyses focused on aggregate service use by MA and TM decedents nationally and did not assess potential geographic variations that might exist in the differences we identified. Our analyses did not include enrollees in preferred provider organizations or private fee-for-service plans. We were unable to assess the appropriateness of service utilization. Similarly, we lacked information on subsets of procedures with particular relevance to end-of-life care (eg, intubation and feeding tube placement during inpatient stays) and on postacute care use (eg, home health).
Aligning health care delivery with patient preferences and reducing the use of unnecessary, burdensome procedures at the end of life present major challenges for the US health care system. As more beneficiaries enroll in MA plans, managed care will play an increasing role in shaping end-oflife care delivery for older Americans. Our study provides the first comprehensive assessment of utilization rates for comparable MA and TM decedents, but important questions remain unanswered. In addition to assessing the mechanisms through which MA plans achieve lower intensity care at the end of life, future research should assess the quality of endof-life care across the MA and TM programs and seek a broader understanding of the potential strengths and limitations of integrated financing and delivery models for individuals at the end of life.
